Neuren Pharmaceuticals Ltd (ASX:NEU) is preparing to outline the company's Phase 2 clinical trial of trofinetide in moderate to severe traumatic brain injury.
Neuren’s program is receiving valuable support from rettsyndrome.org, including grant funding towards the cost of this pediatric trial.
The randomized, double-blind, placebo-controlled, dose-ranging study in subjects aged 5 to 15 years is being conducted at up to 12 sites across the United States, led by clinicians experienced in Rett syndrome including the experts who led Neuren’s first trial in adolescents and adults.
The ASX has this morning granted the company a trading halt to prepare.
The halt will remain in place until the opening of trade on Wednesday 27th April 2016, or earlier if an announcement is made to the market.
Proactive Investors is a global leader reporting financial news, media, research and hosts events for listed emerging growth companies and investors across four continents.